171 related articles for article (PubMed ID: 20006399)
1. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference.
Dufour JF; Johnson P
J Hepatol; 2010 Feb; 52(2):296-304. PubMed ID: 20006399
[No Abstract] [Full Text] [Related]
2. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Jelic S; Sotiropoulos GC;
Ann Oncol; 2010 May; 21 Suppl 5():v59-64. PubMed ID: 20555104
[No Abstract] [Full Text] [Related]
3. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
4. [Hepatocellular carcinoma: what's new?].
Teufel A; Marquardt JU; Galle PR; Wörns M
Dtsch Med Wochenschr; 2012 Feb; 137(5):210-3. PubMed ID: 22250042
[No Abstract] [Full Text] [Related]
5. Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials?
Majno P; Giostra E; Mentha G
Liver Transpl; 2007 Nov; 13(11 Suppl 2):S27-35. PubMed ID: 17969086
[No Abstract] [Full Text] [Related]
6. Hepatocellular carcinoma (primary cancer of the liver).
Barbare JC; Boige V; Boudjema K; Lescesne R; Trinchet JC
Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S57-2S61. PubMed ID: 17151564
[No Abstract] [Full Text] [Related]
7. A new way to look at liver cancer.
Locker J
Hepatology; 2004 Sep; 40(3):521-3. PubMed ID: 15349888
[No Abstract] [Full Text] [Related]
8. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) - European Organisation for Research and Treatment of Cancer (EORTC) guidelines.
Tsochatzis E; Meyer T; O'Beirne J; Burroughs AK
Eur J Cancer; 2013 Apr; 49(6):1509-10. PubMed ID: 23231982
[No Abstract] [Full Text] [Related]
10. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.
Llovet JM; Villanueva A; Marrero JA; Schwartz M; Meyer T; Galle PR; Lencioni R; Greten TF; Kudo M; Mandrekar SJ; Zhu AX; Finn RS; Roberts LR;
Hepatology; 2021 Jan; 73 Suppl 1():158-191. PubMed ID: 32430997
[No Abstract] [Full Text] [Related]
11. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies.
Tournoux C; Paoletti X; Barbare JC
Cancer Treat Rev; 2007 Dec; 33(8):762-3. PubMed ID: 17643827
[No Abstract] [Full Text] [Related]
12. [Hepatocellular carcinoma - current aspects of screening, surveillance and therapeutic strategies (revised EASL-EORTC recommendations)].
Roeb E
Zentralbl Chir; 2014 Apr; 139(2):175-83. PubMed ID: 24132679
[TBL] [Abstract][Full Text] [Related]
13. Down-staging of hepatocellular carcinoma before liver transplantation: should we change our clinical practice?
Ravaioli M; Grazi GL; Cescon M; Ercolani G; Pinna AD; Piscaglia F; Trevisani F
Ann Surg; 2009 Aug; 250(2):348; author reply 348-9. PubMed ID: 19638902
[No Abstract] [Full Text] [Related]
14. Clinical and molecular classification of hepatocellular carcinoma.
Llovet JM
Liver Transpl; 2007 Nov; 13(11 Suppl 2):S13-6. PubMed ID: 17969094
[No Abstract] [Full Text] [Related]
15. Molecular prognostication of liver cancer: end of the beginning.
Thorgeirsson SS; Lee JS; Grisham JW
J Hepatol; 2006 Apr; 44(4):798-805. PubMed ID: 16488507
[No Abstract] [Full Text] [Related]
16. Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?
Wang W; Zhao Y; Han G; Fan D
J Hepatol; 2012 Jul; 57(1):224-5; author reply 225-6. PubMed ID: 22326644
[No Abstract] [Full Text] [Related]
17. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Jelic S;
Ann Oncol; 2009 May; 20 Suppl 4():41-5. PubMed ID: 19454459
[No Abstract] [Full Text] [Related]
18. Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making.
Addissie BD; Roberts LR
Clin Liver Dis; 2015 May; 19(2):277-94. PubMed ID: 25921663
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatocellular carcinoma in cirrhosis: locoregional therapies for bridging to liver transplant.
Lee FT
Liver Transpl; 2007 Nov; 13(11 Suppl 2):S24-6. PubMed ID: 17969066
[No Abstract] [Full Text] [Related]
20. Transarterial chemoembolization using doxorubicin beads for unresectable hepatocellular carcinoma.
Poston GJ
Onkologie; 2010; 33(1-2):5-6. PubMed ID: 20164653
[No Abstract] [Full Text] [Related]
[Next] [New Search]
